88 related articles for article (PubMed ID: 24378283)
1. Re-treatment of chronic HCV infection in HIV co-infected patients and predictors of sustained viral response.
Krastinova E; Bani-Sadr F; Fromentin D; Goujard C; Hessamfar M; Yazdanpanah Y; Pol S; Cacoub P; Perronne C; Carrat F
J Infect; 2014 May; 68(5):462-6. PubMed ID: 24378283
[TBL] [Abstract][Full Text] [Related]
2. Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy.
Rivero-Juarez A; Neukam K; Labarga P; Camacho A; Macias J; Barreiro P; Torre-Cisneros J; Pineda JA; Soriano V; Rivero A
J Infect; 2014 Apr; 68(4):372-7. PubMed ID: 24269677
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
[TBL] [Abstract][Full Text] [Related]
4. Response to interferon-based therapies in HIV-infected patients with chronic hepatitis C due to genotype 4.
Soriano V; Núñez M; Sánchez-Conde M; Barreiro P; García-Samaniego J; Martín-Carbonero L; Romero M; González-Lahoz J
Antivir Ther; 2005; 10(1):167-70. PubMed ID: 15751774
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the PKR-eIF2alpha phosphorylation homology domain (PePHD) of hepatitis C virus genotype 1 in HIV-coinfected patients by ultra-deep pyrosequencing and its relationship to responses to pegylated interferon-ribavirin treatment.
Bolcic F; Sede M; Moretti F; Westergaard G; Vazquez M; Laufer N; Quarleri J
Arch Virol; 2012 Apr; 157(4):703-11. PubMed ID: 22270759
[TBL] [Abstract][Full Text] [Related]
6. Viral decline over 48h and HCV amino acid mutations are related to efficacy of PEG-IFN/ribavirin.
Miyasaka A; Kumagai I; Abe K; Suzuki K
Hepatogastroenterology; 2012 May; 59(115):794-9. PubMed ID: 22020909
[TBL] [Abstract][Full Text] [Related]
7. Regression of liver fibrosis is progressive after sustained virological response to HCV therapy in patients with hepatitis C and HIV coinfection.
Casado JL; Quereda C; Moreno A; Pérez-Elías MJ; Martí-Belda P; Moreno S
J Viral Hepat; 2013 Dec; 20(12):829-37. PubMed ID: 24304452
[TBL] [Abstract][Full Text] [Related]
8. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus.
Berenguer J; Alvarez-Pellicer J; Martín PM; López-Aldeguer J; Von-Wichmann MA; Quereda C; Mallolas J; Sanz J; Tural C; Bellón JM; González-García J;
Hepatology; 2009 Aug; 50(2):407-13. PubMed ID: 19575364
[TBL] [Abstract][Full Text] [Related]
9. Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naïve Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study.
Liu CH; Sheng WH; Sun HY; Hsieh SM; Lo YC; Liu CJ; Su TH; Yang HC; Liu WC; Chen PJ; Chen DS; Hung CC; Kao JH
Sci Rep; 2015 Nov; 5():17410. PubMed ID: 26616669
[TBL] [Abstract][Full Text] [Related]
10. Antiretroviral therapy does not affect response to chronic hepatitis C therapy in HIV-coinfected patients.
De Leon LB; Tovo CV; Kliemann DA; De Mattos AA; Feltrin AA; Pacheco LS; De Almeida PR
J Infect Dev Ctries; 2016 Aug; 10(7):762-9. PubMed ID: 27482809
[TBL] [Abstract][Full Text] [Related]
11. Low rates of sustained virologic response with peginterferon plus ribavirin for chronic hepatitis C virus infection in HIV infected patients in Rio de Janeiro, Brazil.
Barcaui HS; Tavares GC; May SB; Brandão-Mello CE; Amendola Pires MM; Barroso PF
PLoS One; 2013; 8(7):e67734. PubMed ID: 23874441
[TBL] [Abstract][Full Text] [Related]
12. [Comparison of hepatitis C viral RNA and core antigen kinetics in the therapeutic follow up of hepatitis C virus and human immunodeficiency virus co-infected patients, treated by bitherapy interferon-ribavirin, within the framework of RIBAVIC protocol].
Pivert A; Payan C; Lunel F;
Pathol Biol (Paris); 2004 Nov; 52(9):522-8. PubMed ID: 15531116
[TBL] [Abstract][Full Text] [Related]
13. Low levels of microbial translocation marker LBP are associated with sustained viral response after anti-HCV treatment in HIV-1/HCV co-infected patients.
Nyström J; Stenkvist J; Häggblom A; Weiland O; Nowak P
PLoS One; 2015; 10(3):e0118643. PubMed ID: 25785448
[TBL] [Abstract][Full Text] [Related]
14. Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among HIV/HCV-coinfected patients.
ANRS CO13 HEPAVIH Cohort
AIDS; 2015 Sep; 29(14):1821-30. PubMed ID: 26372388
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of cost-effectiveness of peginterferon plus ribavirin for chronic hepatitis C treatment and direct-acting antiviral agents among HIV-infected patients in the prison and community settings.
Chen CP; Cheng CY; Zou H; Cheng CH; Cheng SH; Chen CK; Chen CH; Bair MJ
J Microbiol Immunol Infect; 2019 Aug; 52(4):556-562. PubMed ID: 30360951
[TBL] [Abstract][Full Text] [Related]
16. Present, old and future strategies for anti-HCV treatment in patients infected by genotype-1: estimation of the drug costs in the Calabria Region in the era of the directly acting antivirals.
Strazzulla A; Costa C; Pisani V; De Maria V; Giancotti F; Di Salvo S; Parisi SG; Basso M; Franzetti MM; Marascio N; Liberto MC; Barreca GS; Lamberti AG; Zicca E; Postorino MC; Matera G; Focà A; Torti C
BMC Infect Dis; 2014; 14 Suppl 5(Suppl 5):S3. PubMed ID: 25236374
[TBL] [Abstract][Full Text] [Related]
17. NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patients.
El-Shamy A; Shoji I; El-Akel W; Bilasy SE; Deng L; El-Raziky M; Jiang DP; Esmat G; Hotta H
J Clin Microbiol; 2012 Dec; 50(12):3886-92. PubMed ID: 22993188
[TBL] [Abstract][Full Text] [Related]
18. Immunodeficiency and intrinsic IFN resistance are associated with viral breakthrough to HCV therapy in HIV-coinfected patients.
Nussenblatt V; McLaughlin M; Rehm CA; Lempicki RA; Brann T; Yang J; Proschan M; Highbarger HC; Dewar RL; Imamichi T; Koratich C; Neumann AU; Masur H; Polis MA; Kottilil S
AIDS Res Hum Retroviruses; 2007 Nov; 23(11):1354-9. PubMed ID: 18184077
[TBL] [Abstract][Full Text] [Related]
19. Short article: Fatigue in the long term after HCV treatment in HIV-HCV-coinfected patients: functional limitations persist despite viral clearance in patients exposed to peg-interferon/ribavirin-containing regimens (ANRS CO13-HEPAVIH cohort).
Marcellin F; Protopopescu C; Poizot-Martin I; Miailhes P; Esterle L; Wittkop L; Spire B; Bocquier A; Salmon-Ceron D; Dabis F; Carrieri MP;
Eur J Gastroenterol Hepatol; 2016 Sep; 28(9):1003-7. PubMed ID: 27177169
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of the cellular immune response in HIV/HCV patients with hemophilia during peginterferon/ribavirin therapy in southern China.
Yingying L; Jiangrong W; Jing L
Diagn Microbiol Infect Dis; 2014 Jan; 78(1):45-8. PubMed ID: 24183601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
